Press Release
Digbi Health in the news
Featured Press
Digbi Health features in the Top 10 Startups of LG’s ‘Mission for the Future’ challenge
Chosen ‘Mission for the Future’ Companies and LG to Jointly Pursue Innovative Solutions for Digital Health, the Metaverse and Electric Mobility. The LG Electronics North American Innovation Center, LG NOVA, has selected the Finalist companies for its Mission for the Future global challenge program. Representing multiple potential business paths in three industries, the companies will be working with the LG NOVA team to collaborate on new business ventures, alongside continuing to grow and scale their companies, qualifying for potential investment from LG and other investors within LG NOVA ecosystem to develop impactful solutions for people, communities and the planet.* “This inaugural year of our challenge demonstrated how effective and powerful collaboration between technology startups and established corporations can help accelerate the innovation process,” said LG Electronics Senior Vice President of Innovation Dr. Sokwoo Rhee and head of LG NOVA. “Congratulations to the Finalists and all the companies that participated in the Mission for the Future challenge. We look forward to the journey with these companies innovating for a brighter, more technologically advanced future.” The finalists were selected from an initial pool of approximately 1,300 applicants. They secured the top spot after working closely with the LG NOVA Entrepreneur-In-Residence team over a six- to nine-month period to build and test the proposals. Throughout the process, the companies had opportunities to meet with LG business teams and other investors within the LG NOVA ecosystem. Finalists were presented to LG Electronics Global CEO William Cho. This unique challenge program, which has the opportunity to diversify and expand LG’s technology portfolio, prioritizes innovating for a better life across key impact industries, according to Rhee. “These incredible companies hold the potential of changing the world, and LG looks forward to collaborating with them to leverage innovation to impact society in meaningful ways,” he said. With this selection of companies, LG NOVA will build new businesses in Digital Health, Electric Mobility and the Metaverse and pursue multiple paths to deliver new services and solutions that will help us move forward faster into the future. Digital Health – With digital health capabilities key to enabling the delivery of healthcare to diverse and disparate communities, LG NOVA is working to expand and scale greater access to healthcare and personal health services. Digbi Health: is a digital care platform to prevent and reverse chronic metabolic, digestive and mental health conditions using gut microbiome insight, genetics, AI and food-as-medicine. Together LG and Digbi will work to make care globally accessible at home and the office, and to advance cure. LifeNome: is a B2B2C precision health platform powered by genomics and AI, offering personalized health and well-being solutions to the world's leading enterprises. LG and LifeNome plan to bring to market the world’s first precision maternal and family health platform, supporting pregnant individuals 24/7 from conception all the way to the early stages of a child's life. Mindset Medical: is a sensor-based technology platform that can use a camera in patient-owned devices to virtually capture health and biological readings to assist doctors in enhancing medical diagnosis and treatment effectiveness. Expanding upon new services available to doctors and providers, LG’s work with Mindset Medical is expected to make it easier for medical providers to understand patient health over time or during live virtual doctor visits. XRHealth: develops virtual treatment rooms, integrating immersive VR/AR technology, licensed clinicians and real-time data analytics on one platform, providing a comprehensive therapeutic care solution for patients through the continuum of care, from the hospital to the patient’s home. LG and XRHealth will continue to grow the service offering to deliver more insights to clinicians and enable more precise personalized care. Electric Mobility – With LG’s commitment to sustainability as an organization, LG NOVA is working to pursue new opportunities to expand access to electric vehicle (EV) and electric mobility solutions by enabling more businesses to leverage their infrastructure to provide EV services. Driivz: empowers major EV service providers with an end-to-end EV charging and smart energy management software platform. LG and Driivz will work together to enable the hospitality industry across the United States to offer EV charging-as-a-service, while optimizing their EV charging operations and providing their customers with an exceptional EV charging experience. I-EMS Solutions, Ltd. uses innovative AI and blockchain-based distributed energy resource management systems (DERMS) and transactive energy software platforms to enable power optimization across smart cities, smart homes, and e-mobility. By working with I-EMS, LG will help modernize the electricity grid and optimize energy management to deliver better power management solutions for the market. SparkCharge: offers an affordable and convenient way for electric vehicle owners to charge their EVs without a direct-access charger at home or on the road. LG and SparkCharge plan to work together to deliver turnkey EV solutions for businesses to create a stream of revenue from their parking spaces. The Metaverse – The Metaverse will bring greater capabilities that will change how we engage across the digital space in the future. LG is looking to broaden its role and explore new services and applications for enterprises that leverage the capabilities of the Metaverse. iQ3 Connect: provides immersive 3D workspace technology to enable distributed teams to cost-effectively work, collaborate and train from anywhere, on any AR, VR, or 2D device. LG will work with iQ3 Connect to deploy immersive training and realtime collaborative workspace solutions for enterprises. NeuroTrainer: is a brain training and optimization platform deployed in VR to create immersive environments and training protocols that utilizes the scientific principles of neuroplasticity to enhance focus and cognitive performance. Expanding upon iQ3 capabilities, LG and NeuroTrainer will work together to add platform capabilities and enhancements designed to further refine NeuroTrainer as a powerful tool for corporate wellness and mental resiliency. LG NOVA’s second annual Mission for The Future (2022) is now open for submissions. Deadline to submit is Thursday, Oct. 6, 2022. Please visit www.lgnova.com/mission22 for more information on how to submit new ideas to LG NOVA. *Subject to due diligence and other considerations. # # # About LG NOVA LG NOVA, the North American Innovation Center for global innovation leader LG Electronics, is a team focused on bringing innovation from the outside to LG. LG NOVA is based in Santa Clara, Calif. The center's mission is to build, nurture and grow innovations that impact the future. Learn more about LG NOVA at www.lgnova.com. About LG Electronics USA: LG Electronics USA, Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics, Inc., a $63 billion global innovator in technology and manufacturing. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems, energy solutions and vehicle components. LG is 2022 ENERGY STAR® Partner of the Year-Sustained Excellence. The company’s commitment to environmental sustainability and its “Life’s Good” marketing theme encompass how LG is dedicated to people’s happiness by exceeding expectations today and tomorrow.
Novo Nordisk to explore obesity risk tests with Digbi Health pilot project
Novo Nordisk will begin a pilot project to evaluate how genomic and microbiome-based tests can be used to help prevent obesity. The work is part of a tie-up with Digbi Health and comes as Novo’s Wegovy franchise is expected to keep up its quick growth. The obesity medication was approved in June 2021. Earlier this year, the drugmaker doubled its revenue target for Wegovy, saying it expects to bring in more than $3.7 billion in sales by 2025. By working with Digbi and the startup’s digital screening offerings, the pilot will explore how a person’s genes, proteins, gut bacteria and lifestyle data can help predict whether they have a high or low risk of obesity as well as the range of cardiac and metabolic conditions that may come with it. Obesity-related risks vary significantly by gender and ancestry, and, according to the companies, most weight management programs do not incorporate information from genetics or the gut microbiome. As part of the pilot, Digbi—which offers diagnostic tests and artificial-intelligence-powered coaching programs—has enrolled in Novo Nordisk’s Global Prevention Accelerator Program, which launched last year with a special focus on worldwide obesity. With funding from the Big Pharma, Digbi aims to show its digital care offerings can scale up to reach large numbers of people while also being adaptable for local populations. The companies said they plan to complete the initial steps of the pilot by the end of September before expanding Digbi’s platform to demonstrate large-scale validation through the help of Digbi’s user base. Novo’s accelerator had previously selected Ksana Health, developer of the remote measurement platform Vira, to offer an objective system for tracking behavior patterns and forming personalized care plans. The Danish drugmaker also expanded its research into obesity this year through a collaboration with EraCal Therapeutics, a Swiss biotech that is developing new treatments aimed at food intake regulation, suppressing appetite and other characteristics of metabolism. Also known as semaglutide, Novo Nordisk’s Wegovy was first approved for treating diabetes. It received a new green light in obesity alongside diet and exercise last year based on phase 3 trial data showing it helped one-third of treated patients lose more than 20% of their body weight over about a year and a half. Patients without Type 2 diabetes lost 17% to 18% of their weight on average.
Digbi Health launches Digbi Digestive™, the first gut microbiome and genetic-based digital care program to address IBS and functional digestive disorders affecting 70M Americans.
Digbi Digestive was launched based on a recent real-world outcomes study of members reversing digestive disorders. MOUNTAIN VIEW, Calif. June 16, 2021 -- Overwhelming research now links gut microbiome to mental health, sleep disorders, chronic pain, inflammatory digestive and skin illnesses along with chronic lifestyle illnesses including diabetes and obesity. Digbi Health, the first company with a clinically proven digital genetics and gut-microbiome therapeutic platform program launches Digbi Digestive, a precision care program designed to improve, reverse and monitor gastrointestinal and functional bowel disorders by prescribing food and lifestyle as medicine. Many functional gastrointestinal disorders disproportionately impact women and Caucasians. Digbi Digestive starts with analyzing a member's genetics, gut microbiome, meals, habits, clinical markers of sugar and fat in the blood, to isolate inflammatory interactions and develop deeper understanding of metabolic pathways supported by the gut microbiome like serotonin production which regulates sleep and mental health. Members have direct access to gastrointestinal health trained health coaches for personal nutrition support and guidance with meal planning. The program includes live coaching sessions for managing cravings, stress, and sleep. Members can additionally access ongoing gut microbiome monitoring services and personalized prebiotics. “Gastrointestinal diseases beyond being expensive to payers, employers and individuals are whisper illnesses that are stigmatized and linked to mental health and inflammatory illnesses that seriously affect a person’s quality of life,” said Ranjan Sinha, Founder and CEO, Digbi Health. “We are committed to address the stigma associated with these illnesses and appreciate the support provided to us by payers, TPAs, medical universities, and employers who are enabling no cost or low-cost access to their members and employees. The results of weight loss and disease reversal in our members’ outcomes are the driving forces for making Digbi Digestive available to consumers who cannot access the program through their insurance or employers” Below are the results of the recent real-world study conducted across members of a large insurance payer who experienced improvement of symptoms after Digbi intervention: 83% experienced reduction or reversal of Irritable Bowel Syndrome (IBS) 67% experienced reduction or reversal of Depression 82% experienced reduction or reversal of Heartburn 89% experienced reduction or reversal of Chronic Bloating 77% experienced reduction or reversal of Gassiness 78% experienced reduction or reversal of Chronic Constipation 79% experienced reduction or reversal of Diarrhea "Functional Bowel disorders such as irritable bowel syndrome (IBS) are complex, multifactorial illnesses that arise from the interactions between a person’s genetic, gut microbiome risk profile and lifestyle risk factors, such as stress, insufficient sleep, inflammatory food intake, excessive caloric intake, and medications. Current treatment options may not always take all these factors into consideration", said Dr. Parambir S. Dulai, a gastroenterologist at UC San Diego Medical Center. “The Digbi Health program connects these factors to deliver improved patient health on an individualized basis." “I thought I was eating all the foods that were healthy, but turns out, not for me. I also learned I’m gluten-sensitive and never believed this was a thing until I made changes to my diet. The results have been astounding. I was living with chronic gut and digestive issues and now no longer suffer and have been able to get off my medications,” said Digbi member, Anna K. Learn more about Digbi Digestive. Video by Digbi Health About Digbi Health Digbi Health is a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity-related gut, skin disorders, hypertension and other cardiometabolic health management programs based on an individual’s gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health is prescribed by doctors, health care providers, and insurance companies.Follow us on LinkedIn, Twitter, Instagram, and Facebook.
Latest Press
Digbi Health features in the Top 10 Startups of LG’s ‘Mission for the Future’ challenge
Chosen ‘Mission for the Future’ Companies and LG to Jointly Pursue Innovative Solutions for Digital Health, the Metaverse and Electric Mobility. The LG Electronics North American Innovation Center, LG NOVA, has selected the Finalist companies for its Mission for the Future global challenge program. Representing multiple potential business paths in three industries, the companies will be working with the LG NOVA team to collaborate on new business ventures, alongside continuing to grow and scale their companies, qualifying for potential investment from LG and other investors within LG NOVA ecosystem to develop impactful solutions for people, communities and the planet.* “This inaugural year of our challenge demonstrated how effective and powerful collaboration between technology startups and established corporations can help accelerate the innovation process,” said LG Electronics Senior Vice President of Innovation Dr. Sokwoo Rhee and head of LG NOVA. “Congratulations to the Finalists and all the companies that participated in the Mission for the Future challenge. We look forward to the journey with these companies innovating for a brighter, more technologically advanced future.” The finalists were selected from an initial pool of approximately 1,300 applicants. They secured the top spot after working closely with the LG NOVA Entrepreneur-In-Residence team over a six- to nine-month period to build and test the proposals. Throughout the process, the companies had opportunities to meet with LG business teams and other investors within the LG NOVA ecosystem. Finalists were presented to LG Electronics Global CEO William Cho. This unique challenge program, which has the opportunity to diversify and expand LG’s technology portfolio, prioritizes innovating for a better life across key impact industries, according to Rhee. “These incredible companies hold the potential of changing the world, and LG looks forward to collaborating with them to leverage innovation to impact society in meaningful ways,” he said. With this selection of companies, LG NOVA will build new businesses in Digital Health, Electric Mobility and the Metaverse and pursue multiple paths to deliver new services and solutions that will help us move forward faster into the future. Digital Health – With digital health capabilities key to enabling the delivery of healthcare to diverse and disparate communities, LG NOVA is working to expand and scale greater access to healthcare and personal health services. Digbi Health: is a digital care platform to prevent and reverse chronic metabolic, digestive and mental health conditions using gut microbiome insight, genetics, AI and food-as-medicine. Together LG and Digbi will work to make care globally accessible at home and the office, and to advance cure. LifeNome: is a B2B2C precision health platform powered by genomics and AI, offering personalized health and well-being solutions to the world's leading enterprises. LG and LifeNome plan to bring to market the world’s first precision maternal and family health platform, supporting pregnant individuals 24/7 from conception all the way to the early stages of a child's life. Mindset Medical: is a sensor-based technology platform that can use a camera in patient-owned devices to virtually capture health and biological readings to assist doctors in enhancing medical diagnosis and treatment effectiveness. Expanding upon new services available to doctors and providers, LG’s work with Mindset Medical is expected to make it easier for medical providers to understand patient health over time or during live virtual doctor visits. XRHealth: develops virtual treatment rooms, integrating immersive VR/AR technology, licensed clinicians and real-time data analytics on one platform, providing a comprehensive therapeutic care solution for patients through the continuum of care, from the hospital to the patient’s home. LG and XRHealth will continue to grow the service offering to deliver more insights to clinicians and enable more precise personalized care. Electric Mobility – With LG’s commitment to sustainability as an organization, LG NOVA is working to pursue new opportunities to expand access to electric vehicle (EV) and electric mobility solutions by enabling more businesses to leverage their infrastructure to provide EV services. Driivz: empowers major EV service providers with an end-to-end EV charging and smart energy management software platform. LG and Driivz will work together to enable the hospitality industry across the United States to offer EV charging-as-a-service, while optimizing their EV charging operations and providing their customers with an exceptional EV charging experience. I-EMS Solutions, Ltd. uses innovative AI and blockchain-based distributed energy resource management systems (DERMS) and transactive energy software platforms to enable power optimization across smart cities, smart homes, and e-mobility. By working with I-EMS, LG will help modernize the electricity grid and optimize energy management to deliver better power management solutions for the market. SparkCharge: offers an affordable and convenient way for electric vehicle owners to charge their EVs without a direct-access charger at home or on the road. LG and SparkCharge plan to work together to deliver turnkey EV solutions for businesses to create a stream of revenue from their parking spaces. The Metaverse – The Metaverse will bring greater capabilities that will change how we engage across the digital space in the future. LG is looking to broaden its role and explore new services and applications for enterprises that leverage the capabilities of the Metaverse. iQ3 Connect: provides immersive 3D workspace technology to enable distributed teams to cost-effectively work, collaborate and train from anywhere, on any AR, VR, or 2D device. LG will work with iQ3 Connect to deploy immersive training and realtime collaborative workspace solutions for enterprises. NeuroTrainer: is a brain training and optimization platform deployed in VR to create immersive environments and training protocols that utilizes the scientific principles of neuroplasticity to enhance focus and cognitive performance. Expanding upon iQ3 capabilities, LG and NeuroTrainer will work together to add platform capabilities and enhancements designed to further refine NeuroTrainer as a powerful tool for corporate wellness and mental resiliency. LG NOVA’s second annual Mission for The Future (2022) is now open for submissions. Deadline to submit is Thursday, Oct. 6, 2022. Please visit www.lgnova.com/mission22 for more information on how to submit new ideas to LG NOVA. *Subject to due diligence and other considerations. # # # About LG NOVA LG NOVA, the North American Innovation Center for global innovation leader LG Electronics, is a team focused on bringing innovation from the outside to LG. LG NOVA is based in Santa Clara, Calif. The center's mission is to build, nurture and grow innovations that impact the future. Learn more about LG NOVA at www.lgnova.com. About LG Electronics USA: LG Electronics USA, Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics, Inc., a $63 billion global innovator in technology and manufacturing. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems, energy solutions and vehicle components. LG is 2022 ENERGY STAR® Partner of the Year-Sustained Excellence. The company’s commitment to environmental sustainability and its “Life’s Good” marketing theme encompass how LG is dedicated to people’s happiness by exceeding expectations today and tomorrow.
Novo Nordisk to explore obesity risk tests with Digbi Health pilot project
Novo Nordisk will begin a pilot project to evaluate how genomic and microbiome-based tests can be used to help prevent obesity. The work is part of a tie-up with Digbi Health and comes as Novo’s Wegovy franchise is expected to keep up its quick growth. The obesity medication was approved in June 2021. Earlier this year, the drugmaker doubled its revenue target for Wegovy, saying it expects to bring in more than $3.7 billion in sales by 2025. By working with Digbi and the startup’s digital screening offerings, the pilot will explore how a person’s genes, proteins, gut bacteria and lifestyle data can help predict whether they have a high or low risk of obesity as well as the range of cardiac and metabolic conditions that may come with it. Obesity-related risks vary significantly by gender and ancestry, and, according to the companies, most weight management programs do not incorporate information from genetics or the gut microbiome. As part of the pilot, Digbi—which offers diagnostic tests and artificial-intelligence-powered coaching programs—has enrolled in Novo Nordisk’s Global Prevention Accelerator Program, which launched last year with a special focus on worldwide obesity. With funding from the Big Pharma, Digbi aims to show its digital care offerings can scale up to reach large numbers of people while also being adaptable for local populations. The companies said they plan to complete the initial steps of the pilot by the end of September before expanding Digbi’s platform to demonstrate large-scale validation through the help of Digbi’s user base. Novo’s accelerator had previously selected Ksana Health, developer of the remote measurement platform Vira, to offer an objective system for tracking behavior patterns and forming personalized care plans. The Danish drugmaker also expanded its research into obesity this year through a collaboration with EraCal Therapeutics, a Swiss biotech that is developing new treatments aimed at food intake regulation, suppressing appetite and other characteristics of metabolism. Also known as semaglutide, Novo Nordisk’s Wegovy was first approved for treating diabetes. It received a new green light in obesity alongside diet and exercise last year based on phase 3 trial data showing it helped one-third of treated patients lose more than 20% of their body weight over about a year and a half. Patients without Type 2 diabetes lost 17% to 18% of their weight on average.
Digbi Health launches Digbi Digestive™, the first gut microbiome and genetic-based digital care program to address IBS and functional digestive disorders affecting 70M Americans.
Digbi Digestive was launched based on a recent real-world outcomes study of members reversing digestive disorders. MOUNTAIN VIEW, Calif. June 16, 2021 -- Overwhelming research now links gut microbiome to mental health, sleep disorders, chronic pain, inflammatory digestive and skin illnesses along with chronic lifestyle illnesses including diabetes and obesity. Digbi Health, the first company with a clinically proven digital genetics and gut-microbiome therapeutic platform program launches Digbi Digestive, a precision care program designed to improve, reverse and monitor gastrointestinal and functional bowel disorders by prescribing food and lifestyle as medicine. Many functional gastrointestinal disorders disproportionately impact women and Caucasians. Digbi Digestive starts with analyzing a member's genetics, gut microbiome, meals, habits, clinical markers of sugar and fat in the blood, to isolate inflammatory interactions and develop deeper understanding of metabolic pathways supported by the gut microbiome like serotonin production which regulates sleep and mental health. Members have direct access to gastrointestinal health trained health coaches for personal nutrition support and guidance with meal planning. The program includes live coaching sessions for managing cravings, stress, and sleep. Members can additionally access ongoing gut microbiome monitoring services and personalized prebiotics. “Gastrointestinal diseases beyond being expensive to payers, employers and individuals are whisper illnesses that are stigmatized and linked to mental health and inflammatory illnesses that seriously affect a person’s quality of life,” said Ranjan Sinha, Founder and CEO, Digbi Health. “We are committed to address the stigma associated with these illnesses and appreciate the support provided to us by payers, TPAs, medical universities, and employers who are enabling no cost or low-cost access to their members and employees. The results of weight loss and disease reversal in our members’ outcomes are the driving forces for making Digbi Digestive available to consumers who cannot access the program through their insurance or employers” Below are the results of the recent real-world study conducted across members of a large insurance payer who experienced improvement of symptoms after Digbi intervention: 83% experienced reduction or reversal of Irritable Bowel Syndrome (IBS) 67% experienced reduction or reversal of Depression 82% experienced reduction or reversal of Heartburn 89% experienced reduction or reversal of Chronic Bloating 77% experienced reduction or reversal of Gassiness 78% experienced reduction or reversal of Chronic Constipation 79% experienced reduction or reversal of Diarrhea "Functional Bowel disorders such as irritable bowel syndrome (IBS) are complex, multifactorial illnesses that arise from the interactions between a person’s genetic, gut microbiome risk profile and lifestyle risk factors, such as stress, insufficient sleep, inflammatory food intake, excessive caloric intake, and medications. Current treatment options may not always take all these factors into consideration", said Dr. Parambir S. Dulai, a gastroenterologist at UC San Diego Medical Center. “The Digbi Health program connects these factors to deliver improved patient health on an individualized basis." “I thought I was eating all the foods that were healthy, but turns out, not for me. I also learned I’m gluten-sensitive and never believed this was a thing until I made changes to my diet. The results have been astounding. I was living with chronic gut and digestive issues and now no longer suffer and have been able to get off my medications,” said Digbi member, Anna K. Learn more about Digbi Digestive. Video by Digbi Health About Digbi Health Digbi Health is a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity-related gut, skin disorders, hypertension and other cardiometabolic health management programs based on an individual’s gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health is prescribed by doctors, health care providers, and insurance companies.Follow us on LinkedIn, Twitter, Instagram, and Facebook.
